article thumbnail

A perfect storm for biotech stocks

World of DTC Marketing

It dropped more than 15% in 2016 and followed that up with a 44% rise in 2017. Meanwhile, the Food and Drug Administration has delayed several drug approvals, and Sen. introduced sweeping drug-pricing legislation. 1ne: More scrutinization by the FDA on new drug applications. Bernie Sanders, I-Vt.,

article thumbnail

Innovative personalised immunotherapy approved for multiple myeloma

European Pharmaceutical Review

The first BCMA-targeted CAR-T cell therapy for second-line treatment of multiple myeloma has been approved by the US Food and Drug Administration (FDA). Janssen), a Johnson & Johnson company in December 2017.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

A scientific approach to irrational consumer choices

World of DTC Marketing

GOOD MORNING: The FDA is taking a scientific approach to evaluating direct-to-consumer (DTC) drug advertising, focusing on measuring consumer perceptions of the information presented in ads. Presenting quantitative information increased participants’ gist and verbatim recall of drug efficacy. ” Uh…no.

article thumbnail

Janssen seeks US FDA approval of new indication for Carvykti

Pharma Leaders

The Janssen Pharmaceutical Companies of Johnson & Johnson is seeking approval of a new indication for Carvykti (ciltacabtagene autoleucel; cilta-cel) from the US Food and Drug Administration (FDA) through submission of a supplemental Biologics License Application (sBLA).

article thumbnail

What gene therapy manufacturers can gain from collaboration

European Pharmaceutical Review

Growth has been rapid since Europe’s first gene therapy approval in 2012, 2 and the first US Food and Drug Administration (FDA) approval of a gene therapy in 2017.

article thumbnail

US FDA expands approval for Merck’s PREVYMIS (letermovir)

Pharmaceutical Technology

The US Food and Drug Administration (FDA) has granted approval for a new indication for Merck’s PREVYMIS (letermovir) to prevent cytomegalovirus (CMV) disease in high-risk adult kidney transplant recipients. The latest move follows a priority review of a supplemental new drug application (sNDA) for the therapy.

article thumbnail

CHMP to review MAA for geographic atrophy treatment

European Pharmaceutical Review

ACP was approved by the US Food and Drug Administration (FDA) as IZERVAY (avacincaptad pegol intravitreal solution) for geographic atrophy (GA) secondary to age-related macular degeneration (AMD) on 4 August 2023. This could therefore potentially slow the progression of GA.